UY34216A - Nuevos compuestos que inhiben la actividad de la Lp-PLA2 - Google Patents

Nuevos compuestos que inhiben la actividad de la Lp-PLA2

Info

Publication number
UY34216A
UY34216A UY0001034216A UY34216A UY34216A UY 34216 A UY34216 A UY 34216A UY 0001034216 A UY0001034216 A UY 0001034216A UY 34216 A UY34216 A UY 34216A UY 34216 A UY34216 A UY 34216A
Authority
UY
Uruguay
Prior art keywords
pla2
activity
inhibit
new compounds
atherosclerosis
Prior art date
Application number
UY0001034216A
Other languages
English (en)
Spanish (es)
Inventor
Wan Zehong
Yu Haihua
Long Kai
Zhang Xiaomin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY34216A publication Critical patent/UY34216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001034216A 2011-07-27 2012-07-25 Nuevos compuestos que inhiben la actividad de la Lp-PLA2 UY34216A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011077702 2011-07-27

Publications (1)

Publication Number Publication Date
UY34216A true UY34216A (es) 2013-02-28

Family

ID=46579034

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034216A UY34216A (es) 2011-07-27 2012-07-25 Nuevos compuestos que inhiben la actividad de la Lp-PLA2

Country Status (13)

Country Link
US (2) US9273054B2 (enExample)
EP (1) EP2736908A1 (enExample)
JP (1) JP2014521625A (enExample)
KR (1) KR20140059204A (enExample)
CN (1) CN103827118B (enExample)
AR (1) AR087309A1 (enExample)
AU (1) AU2012288865B2 (enExample)
BR (1) BR112014001634A2 (enExample)
CA (1) CA2843102A1 (enExample)
RU (1) RU2014107486A (enExample)
TW (1) TW201321382A (enExample)
UY (1) UY34216A (enExample)
WO (1) WO2013014185A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273054B2 (en) * 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
US20160029630A1 (en) 2012-11-27 2016-02-04 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
US20150313229A1 (en) 2012-11-27 2015-11-05 Basf Se Substituted [1,2,4] Triazole Compounds
EP2925730A1 (en) 2012-11-27 2015-10-07 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
JP2016505053A (ja) * 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
EP3172211B1 (en) 2014-07-22 2019-07-03 GlaxoSmithKline Intellectual Property Development Limited Tricyclic imidazo-pyrimidinone derivatives for the treatment of diseases mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN105777653A (zh) 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
US20190092789A1 (en) * 2015-09-04 2019-03-28 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
CN111868055B (zh) 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂
CN108947782B (zh) * 2018-08-15 2021-08-24 上海罕道医药科技有限公司 一种溴氟多取代苯甲醛衍生物和制备方法
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN113666930B (zh) * 2020-05-13 2022-10-25 上海纽思克生物科技有限公司 桥环嘧啶酮类化合物、其制备方法、其组合物和用途
JP7595964B2 (ja) * 2020-05-13 2024-12-09 上海紐思克生物科技有限公司 架橋環状ピリミジノン類化合物、その製造方法、その組成物及び使用
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2139862C1 (ru) * 1993-05-12 1999-10-20 Е.И. Дю Пон де Немурс энд Компани Замещенные 4(3н)-хиназолиноны, обладающие фунгицидными свойствами, композиции на их основе и способы борьбы с мучнистой росой
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
WO1996019451A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
HUP9901153A3 (en) 1995-07-01 1999-11-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
WO1997012963A2 (en) 1995-09-29 1997-04-10 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
EP0869943A1 (en) 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
EP0865429A1 (en) 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
CZ341098A3 (cs) 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1999024420A1 (en) 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
DE69911980T2 (de) 1998-08-21 2004-09-09 Smithkline Beecham P.L.C., Brentford Pyrimidinonderivate zur behandlung von atheroscleros
DE60042286D1 (de) 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
DE60139429D1 (de) 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
WO2008048867A2 (en) 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8022057B2 (en) * 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
US9273054B2 (en) * 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors

Also Published As

Publication number Publication date
TW201321382A (zh) 2013-06-01
CA2843102A1 (en) 2013-01-31
AR087309A1 (es) 2014-03-12
BR112014001634A2 (pt) 2017-02-14
US9273054B2 (en) 2016-03-01
EP2736908A1 (en) 2014-06-04
US20130030012A1 (en) 2013-01-31
CN103827118A (zh) 2014-05-28
US20140179716A1 (en) 2014-06-26
WO2013014185A1 (en) 2013-01-31
RU2014107486A (ru) 2015-09-10
AU2012288865B2 (en) 2015-10-01
KR20140059204A (ko) 2014-05-15
JP2014521625A (ja) 2014-08-28
CN103827118B (zh) 2016-03-09
AU2012288865A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34039A (es) Compuestos fungicidas
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CR20130539A (es) Triazolopiridinas
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
BR112014017799A8 (pt) Compostos inibidores de metaloenzima
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
UY34765A (es) Compuestos novedosos.
UY34146A (es) Compuestos inhibidores de metaloenzimas
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34559A (es) Inhibidores de bromodominios
UY34817A (es) Tienopirimidinas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY33925A (es) Inhibidores tricíclicos de quinasas
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34374A (es) Benzilindazoles sustituidos
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UY34550A (es) Bencilpirazoles sustituidos
UY34280A (es) Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa.
UY4175Q (es) Reloj pulsera